Results - Announcements
Mankind Pharma Ltd share price inched up 3.83% to Rs 2302.0 after the company's net profit soared by 24.74% to Rs 716.12 crore, while revenue from operations slightly gained 7.62% to Rs 4337.86 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.54 lakh crore, gaining 3.38%. It has marginally improved by 0.07% over last one week and softened by 3.01% in last one month while the market capitalization of Mankind Pharma Ltd has improved by 2.22% and 11.20% in the same period respectively.
Profit before tax (PBT) of Mankind Pharma Ltd stood at Rs 929.11 crore in Q3 FY26, surging by 48.89% year-on-year, and jumping 20.75% quarter-on-quarter. EBITDA came in at Rs 1076 crore, rallying 29.77% YoY and rising 6.45% sequentially.
Total expenses saw a slight increase of 6.32% to Rs 3402.34 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 674.81 crore, marginally falling by 1.47% YoY, while employee benefits expense was at Rs 948.94 crore, inching up 3.88% YoY.
For the TTM ended FY26, revenue from operations improved 16.96% to Rs 14277.64 crore, while net profit eased 3.41% to Rs 1938.1 crore, compared to previous TTM. EBITDA surged by 274510% to Rs 3258.62 crore, and PBT slipped by 7.30% to Rs 2332.68 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 3121.29 crore in FY26, as against Rs 2413.38 crore in FY25.
Mankind Pharma Ltd declined by 4.68% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.18% during the same period.